Demanet C, Brissinck J, Moser M, Leo O, Thielemans K
Unit of Hematology-Immunology, Vrije Universiteit Brussel (VUB), Belgium.
Int J Cancer Suppl. 1992;7:67-8.
Numerous in vitro studies have shown that T lymphocytes can be targeted towards any target cell by using bispecific antibodies (bsAbs) with specificity of the CD3/TCR complex and a target cell antigen. We have produced bsAbs directed against the membrane expressed idiotype of the murine B cell lymphomas BCLI and 38C13, and murine CD3 complex. The dual specificity of the hybrid-hybridoma produced monoclonal antibodies (MAbs) could be demonstrated by flow cytometry, the induction of T cell proliferation, the induction of IL2 secretion by polyclonal T cells, and redirected lysis of the relevant target cells. Immunotherapy of tumor bearing animals demonstrated that bsAbs could efficiently target T cells towards the tumor cells, that tumor cell--T cell bridging is established in vivo, and that both T cell subsets contribute to tumor regression resulting in long-term survival and cure of the lymphomas.
众多体外研究表明，通过使用对CD3/TCR复合物和靶细胞抗原具有特异性的双特异性抗体（bsAb），T淋巴细胞可靶向任何靶细胞。我们制备了针对小鼠B细胞淋巴瘤BCLI和38C13的膜表达独特型以及小鼠CD3复合物的双特异性抗体。通过流式细胞术、T细胞增殖的诱导、多克隆T细胞IL2分泌的诱导以及相关靶细胞的重定向裂解，可证明杂交 - 杂交瘤产生的单克隆抗体（mAb）的双重特异性。荷瘤动物的免疫治疗表明，双特异性抗体可有效地将T细胞靶向肿瘤细胞，在体内建立肿瘤细胞 - T细胞桥接，并且两个T细胞亚群均有助于肿瘤消退，从而导致淋巴瘤的长期存活和治愈。
